Tjalf Ziemssen
Tjalf Ziemssen
Verified email at - Homepage
Cited by
Cited by
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Identifying prodromal Parkinson's disease: pre‐motor disorders in Parkinson's disease
RB Postuma, D Aarsland, P Barone, DJ Burn, CH Hawkes, W Oertel, ...
Movement Disorders 27 (5), 617-626, 2012
Stroke-induced immunodepression: experimental evidence and clinical relevance
U Dirnagl, J Klehmet, JS Braun, H Harms, C Meisel, T Ziemssen, K Prass, ...
Stroke 38 (2), 770-773, 2007
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
Glatiramer acetate‐specific T‐helper 1‐and 2‐type cell lines produce BDNF: implications for multiple sclerosis therapy
T Ziemssen, T KuÈmpfel, WEF Klinkert, O Neuhaus, R Hohlfeld
Brain 125 (11), 2381-2391, 2002
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
C Schläger, H Körner, M Krueger, S Vidoli, M Haberl, D Mielke, E Brylla, ...
Nature 530 (7590), 349-353, 2016
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
Non-motor dysfunction in Parkinson's disease
T Ziemssen, H Reichmann
Parkinsonism & related disorders 13 (6), 323-332, 2007
Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study
A Rolfs, F Fazekas, U Grittner, M Dichgans, P Martus, M Holzhausen, ...
Stroke 44 (2), 340-349, 2013
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
K Selmaj, DKB Li, HP Hartung, B Hemmer, L Kappos, MS Freedman, ...
The Lancet Neurology 12 (8), 756-767, 2013
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ...
The Lancet Neurology 16 (3), 189-199, 2017
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis
N Kawakami, S Lassmann, Z Li, F Odoardi, T Ritter, T Ziemssen, ...
The Journal of experimental medicine 199 (2), 185-197, 2004
Multiple sclerosis beyond EDSS: depression and fatigue
T Ziemssen
Journal of the neurological sciences 277, S37-S41, 2009
Optimizing treatment success in multiple sclerosis
T Ziemssen, T Derfuss, N de Stefano, G Giovannoni, F Palavra, D Tomic, ...
Journal of neurology 263, 1053-1065, 2016
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
Molecular biomarkers in multiple sclerosis
T Ziemssen, K Akgün, W Brück
Journal of neuroinflammation 16 (1), 272, 2019
Psychoneuroimmunology–cross-talk between the immune and nervous systems
T Ziemssen, S Kern
Journal of neurology 254, II8-II11, 2007
Cardiovascular autonomic dysfunction in Parkinson's disease
T Ziemssen, H Reichmann
Journal of the neurological sciences 289 (1-2), 74-80, 2010
Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors
I Krause, S Kern, A Horntrich, T Ziemssen
Multiple Sclerosis Journal 19 (13), 1792-1799, 2013
The system can't perform the operation now. Try again later.
Articles 1–20